Sprint Bioscience Valuation
Is SPRINT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SPRINT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SPRINT (SEK1.52) is trading below our estimate of fair value (SEK22.86)
Significantly Below Fair Value: SPRINT is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SPRINT?
Key metric: As SPRINT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is SPRINT's PS Ratio? | |
|---|---|
| PS Ratio | 1.7x |
| Sales | SEK 61.45m |
| Market Cap | SEK 106.27m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.2x |
| Enterprise Value/EBITDA | -4.4x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does SPRINT's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 13.5x | ||
NXTCL NextCell Pharma | 11.4x | n/a | SEK 126.4m |
DEX Dextech Medical | 16.6x | n/a | SEK 75.8m |
SENZA SenzaGen | 3.5x | 31.4% | SEK 206.5m |
BIOVIC B Biovica International | 22.5x | 81.7% | SEK 162.8m |
SPRINT Sprint Bioscience | 1.7x | 27.6% | SEK 105.4m |
Price-To-Sales vs Peers: SPRINT is good value based on its Price-To-Sales Ratio (1.7x) compared to the peer average (13.5x).
Price to Sales Ratio vs Industry
How does SPRINT's PS Ratio compare vs other companies in the SE Biotechs Industry?
| 5 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| Industry Avg. | 11.8x | 17.8% | |
SPRINT Sprint Bioscience | 1.7x | 27.6% | US$9.55m |
XBRANE Xbrane Biopharma | 1.5x | 61.1% | US$28.14m |
PMDS PMD Device Solutions | 0.8x | 62.0% | US$3.29m |
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
| Industry Avg. | 11.8x | 44.9% | |
SPRINT Sprint Bioscience | 1.7x | n/a | US$9.55m |
Price-To-Sales vs Industry: SPRINT is good value based on its Price-To-Sales Ratio (1.7x) compared to the Swedish Biotechs industry average (11.8x).
Price to Sales Ratio vs Fair Ratio
What is SPRINT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.7x |
| Fair PS Ratio | 2.4x |
Price-To-Sales vs Fair Ratio: SPRINT is good value based on its Price-To-Sales Ratio (1.7x) compared to the estimated Fair Price-To-Sales Ratio (2.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
AstraZeneca
UK£154.5b
A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
AZN
UK£1,413.50
7D
-1.8%
1Y
4.5%
PMD Device Solutions
SEK 36.3m
A digital medical device company, develops and sells respiratory monitoring solutions in Ireland.
PMDS
SEK 1.28
7D
-14.7%
1Y
n/a
Swedish Orphan Biovitrum
SEK 99.5b
An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.
SOBI
SEK 290.60
7D
-12.4%
1Y
15.7%